Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma

Partial hepatectomy is still the treatment of choice aiming at a cure for patients with hepatocellular carcinoma(HCC), provided that the patient can tolerate the treatment. For patients with multiple recurrent HCC after partial hepatectomy which cannot be treated by re-hepatectomy or local ablative...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2014-10, Vol.20 (39), p.14505-14509
Main Authors: Huan, Hong-Bo, Lau, Wan-Yee, Xia, Feng, Ma, Kuan-Sheng, Bie, Ping
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biopsy
carcinoma
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Case Report
hepatec-tomy
Hepatectomy
Hepatocellular
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Male
Middle Aged
Neoplasm Recurrence, Local
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Partial
Phenylurea Compounds - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Remission Induction
sora
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Partial hepatectomy is still the treatment of choice aiming at a cure for patients with hepatocellular carcinoma(HCC), provided that the patient can tolerate the treatment. For patients with multiple recurrent HCC after partial hepatectomy which cannot be treated by re-hepatectomy or local ablative therapy, the prognosis is extremely poor. sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC. Here, we present a 56-yearold patient with HCC who showed complete clinical response after sorafenib was used for tumor recurrence which developed 3 mo after partial hepatectomy. There was no evidence of progression of disease for 60 mo till now after continuous treatment with sorafenib.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v20.i39.14505